Compare · DXCM vs NYXH
DXCM vs NYXH
Side-by-side comparison of DexCom Inc. (DXCM) and Nyxoah SA (NYXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NYXH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.76B, about 182.6x NYXH ($130.1M).
- Over the past year, DXCM is down 13.5% and NYXH is down 49.8% - DXCM leads by 36.3 points.
- DXCM has hit the wire 4 times in the past 4 weeks while NYXH has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 8 for NYXH).
- Company
- DexCom Inc.
- Nyxoah SA
- Price
- $61.55-1.84%
- $2.98-2.93%
- Market cap
- $23.76B
- $130.1M
- 1M return
- -7.89%
- -5.85%
- 1Y return
- -13.51%
- -49.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 8
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest NYXH
- SEC Form S-8 filed by Nyxoah SA
- SEC Form 20-F filed by Nyxoah SA
- Publication relating to transparency notifications
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Publication relating to transparency notification
- Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
- Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
- Publication relating to transparency notifications
- Information on the total number of voting rights and shares